{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T17:00:11Z","timestamp":1791910811352,"version":"4.3.4"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Kriser and Netter Foundations"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.jns.2020.117274","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T04:29:38Z","timestamp":1608179378000},"page":"117274","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Ocular myasthenia gravis \u2013 How effective is low dose prednisone long term?"],"prefix":"10.1016","volume":"420","author":[{"given":"Rashmi","family":"Verma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gil I.","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Kupersmith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2020.117274_bb0005","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/mus.20950","article-title":"Lifetime Course of Myasthenia Gravis","volume":"37","author":"Grob","year":"2008","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2020.117274_bb0010","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ncl.2018.01.002","article-title":"Generalized myasthenia gravis: classification, clinical presentation, natural history, and epidemiology","volume":"36","author":"Hehir","year":"2018","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.jns.2020.117274_bb0015","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/1471-2377-10-46","article-title":"Systematic review of population based epidemiological studies in myasthenia gravis","volume":"10","author":"Carr","year":"2010","journal-title":"BMC Neurol."},{"key":"10.1016\/j.jns.2020.117274_bb0020","first-page":"277","article-title":"Ocular myasthenia gravis","volume":"6","author":"Osserman","year":"1967","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.jns.2020.117274_bb0025","doi-asserted-by":"crossref","first-page":"1663","DOI":"10.1212\/WNL.40.11.1663","article-title":"Why are eye muscles frequently involved in Myasthenia Gravis?","volume":"40","author":"Kaminski","year":"1990","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2020.117274_bb0030","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ncl.2018.01.003","article-title":"Ocular Myasthenia","volume":"36","author":"Al-Haidar","year":"2018","journal-title":"Neurol. Clin."},{"key":"10.1016\/j.jns.2020.117274_bb0035","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1007\/s00415-009-5120-8","article-title":"Ocular myasthenia gravis: treatment successes and failures in patients with long-term follow-up","volume":"256","author":"Kupersmith","year":"2009","journal-title":"J. Neurol."},{"key":"10.1016\/j.jns.2020.117274_bb0040","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archopht.1959.04220060057010","article-title":"Evaluation of ocular signs and symptoms in myasthenia Gravis","volume":"62","author":"Schlezinger","year":"1959","journal-title":"Arch Ophthalmol-Chic"},{"key":"10.1016\/j.jns.2020.117274_bb0045","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1002\/ana.410140504","article-title":"Prognosis of Ocular Myasthenia","volume":"14","author":"Bever","year":"1983","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2020.117274_bb0050","series-title":"Myasthenia Gravis and Myasthenic Disorders. Oxford (UK)","first-page":"135","article-title":"Natural History of Myasthenia Gravis","author":"Grob","year":"1999"},{"key":"10.1016\/j.jns.2020.117274_bb0055","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1001\/archneur.60.2.243","article-title":"Development of generalized disease at 2 Years in patients with Ocular Myasthenia Gravis","volume":"60","author":"Kupersmith","year":"2003","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2020.117274_bb0060","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1001\/archneur.1996.00550080128020","article-title":"Beneficial effects of Corticosteroids on Ocular Myasthenia Gravis","volume":"53","author":"Kupersmith","year":"1996","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2020.117274_bb0065","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/bjo.2004.063404","article-title":"Ocular motor dysfunction and ptosis in ocular myasthenia gravis: effects of treatment","volume":"89","author":"Kupersmith","year":"2005","journal-title":"Brit J Ophthalmol"},{"key":"10.1016\/j.jns.2020.117274_bb0070","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1097\/00041327-200312000-00001","article-title":"Does early immunotherapy reduce the conversion of ocular myasthenia gravis to generalized Myasthenia Gravis?","volume":"23","author":"Kupersmith","year":"2003","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.jns.2020.117274_bb0075","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1001\/archneur.57.5.752","article-title":"Treatment of ocular myasthenia. Steroids only when compelled","volume":"57","author":"Kaminski","year":"2000","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2020.117274_bb0080","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.1212\/01.wnl.0000263481.14289.90","article-title":"Evidence report: the medical treatment of ocular myasthenia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology","volume":"68","author":"Benatar","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2020.117274_bb0085","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.jns.2003.08.017","article-title":"The effect of prednisone on the progression from ocular to generalized myasthenia gravis","volume":"217","author":"Monsul","year":"2004","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.jns.2020.117274_bb0090","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1097\/WNO.0b013e3182536558","article-title":"Safety of prednisone for ocular myasthenia Gravis","volume":"32","author":"Bruce","year":"2012","journal-title":"J. Neuroophthalmol."},{"key":"10.1016\/j.jns.2020.117274_bb0095","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0049-0172(91)90051-Z","article-title":"The efficacy and safety of low-dose corticosteroids for rheumatoid arthritis","volume":"21","author":"Caldwell","year":"1991","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jns.2020.117274_bb0100","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/ana.410150316","article-title":"Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients","volume":"15","author":"Pascuzzi","year":"1984","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2020.117274_bb0105","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1600-0404.1988.tb06970.x","article-title":"Ocular Myasthenia: diagnostic and therapeutic problems","volume":"77","author":"Evoli","year":"1988","journal-title":"Acta Neurol. Scand."},{"key":"10.1016\/j.jns.2020.117274_bb0110","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/mus.24769","article-title":"Efficacy of prednisone for the treatment of Ocular Myasthenia (EPITOME): A randomized controlled trial","volume":"53","author":"Benatar","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2020.117274_bb0115","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1001\/archneur.64.12.1790","article-title":"Ocular myasthenia gravis treatment: The case against prednisone therapy and thymectomy","volume":"64","author":"Gilbert","year":"2007","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2020.117274_bb0120","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1212\/WNL.26.8.729","article-title":"Long-term administration of corticosteroids in myasthenia gravis","volume":"26","author":"Mann","year":"1991","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2020.117274_bb0125","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.jocn.2005.12.041","article-title":"Clinical predictors of steroid-induced exacerbation in Myasthenia Gravis","volume":"13","author":"Bae","year":"2006","journal-title":"J. Clin. Neurosci."},{"key":"10.1016\/j.jns.2020.117274_bb0130","article-title":"Corticosteroids for Myasthenia Gravis (Review)","volume":"2","author":"Schneider-Gold","year":"2005","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.jns.2020.117274_bb0135","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1212\/WNL.38.2.258","article-title":"Azathioprine toxicity during long\u2010term immunosuppression\u00a0of generalized myasthenia gravis","volume":"38","author":"Hohlfeld","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2020.117274_bb0140","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/j.1468-1331.2006.01382.x","article-title":"Safety of long-term combined immunosuppressive treatment in Myasthenia Gravis--Analysis of Adverse Effects of 163 Patients","volume":"13","author":"Rozsa","year":"2006","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jns.2020.117274_bb0145","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1136\/jnnp.62.2.156","article-title":"Ocular myasthenia gravis: response to long term immunosuppressive treatment","volume":"62","author":"Sommer","year":"1997","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jns.2020.117274_bb0150","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1212\/01.WNL.0000094122.88929.0B","article-title":"Mycophenolate Mofetil for Myasthenia Gravis: An analysis of efficacy, safety, and tolerability","volume":"61","author":"Meriggioli","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2020.117274_bb0155","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1212\/01.wnl.0000312373.67493.7f","article-title":"A Trial of Mycophenolate Mofetil with Prednisone as Initial Immunotherapy in Myasthenia Gravis","volume":"71","author":"Muscle Study Group","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2020.117274_bb0160","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1002\/mus.21640","article-title":"Mycophenalate mofetil in AchR-antibody-positive myasthenia gravis: outcome in 102 patients","volume":"41","author":"Hehir","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.jns.2020.117274_bb0165","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00041327-200312000-00002","article-title":"Immunotherapy of ocular myasthenia gravis reduces conversion to Generalized Myasthenia Gravis","volume":"23","author":"Mee","year":"2003","journal-title":"J. Neuroophthalmol."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20306109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X20306109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:53:24Z","timestamp":1758383604000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X20306109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":33,"alternative-id":["S0022510X20306109"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2020.117274","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular myasthenia gravis \u2013 How effective is low dose prednisone long term?","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2020.117274","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"117274"}}